RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Scleroderma outlook improves as survival increases

Jul 12, 2007 - 4:00:00 AM
They found survival improved in each of the five-year periods, and that the frequency of death due to renal crisis significantly decreased over the 30 years, from 42 percent to 6 percent. But the proportion of patients who died from pulmonary fibrosis increased from 6 percent to 33 percent, Steen said. The frequency of pulmonary hypertension also increased, but there was no change in gastrointestinal and heart-related deaths.

 
[RxPG] Washington, D.C. -- Individuals with scleroderma are living significantly longer today, compared with 30 years ago, and the physicians who treat this rare disease of connective tissue hope the newer drugs now on the market may extend lives even further.

Scleroderma, a rare autoimmune disorder of unknown origin, results when collagen builds up in the body’s connective tissue and causes thickening of the skin. In the chronic and often progressive systemic form, scleroderma causes stiff joints and hardening of the internal organs and blood vessels.

In the July issue of the journal Annals of the Rheumatic Diseases, Georgetown University Medical Center professor Virginia Steen, M.D., studied 2,000 patients with scleroderma (also known as systemic sclerosis) treated between 1972 and 2001 at the University of Pittsburgh and found that 10-year survival steadily improved over those years by 12 percent-- from 54 percent to 66 percent.

“This is really good progress, which we hope to improve upon,” said Steen, a leading expert on the disorder who has helped make Georgetown University Hospital a national treatment center for scleroderma. In the 1980s, while at the University of Pittsburgh, she developed a natural history database of scleroderma patients and this database has continued to evolve into the largest in the United States.

The reason overall mortality has dropped, Steen says, is partly because a class of medications, angiotensin converting enzyme (ACE) inhibitors became available which dramatically improved the treatment of renal crisis. Renal crisis used to be almost always fatal and now it is a very treatable complication of scleroderma, she said. Now pulmonary arterial hypertension and pulmonary fibrosis, a condition that is traditionally the second-most frequent cause of death, is responsible for most of the mortality, but these conditions may be increasingly treatable, she said. Patients may develop either disorder, or both.

“Before, it was kidney and then lung disorders that affected most of our patients, and now that we have successfully treated the kidneys, mortality due to lung disease has become the issue,” Steen said. “We are working on ways to use the newer medications to help treat these disorders, hoping to further improve overall survival.”

While all scleroderma-related disorders are believed to affect as many as 900,000 people in the United States, only between 40,000 and 165,000 are diagnosed with systemic scleroderma, according to the National Institutes of Health (NIH). Like all scleroderma disorders, systemic scleroderma affects more women than men, and varies in severity.

In this study, Steen collaborated with co-author Thomas Medsger, M.D., professor of medicine at the University of Pittsburgh to study patients with systemic scleroderma enrolled in the registry. They studied patients evaluated at the University of Pittsburgh between 1972 and 2001, dividing them into five-year time periods, depending on when they were seen.

They found survival improved in each of the five-year periods, and that the frequency of death due to renal crisis significantly decreased over the 30 years, from 42 percent to 6 percent. But the proportion of patients who died from pulmonary fibrosis increased from 6 percent to 33 percent, Steen said. The frequency of pulmonary hypertension also increased, but there was no change in gastrointestinal and heart-related deaths.

“Use of ACE inhibitors made all the difference in saving patients from renal failure, and now it is important that physicians use drugs now available to treat lung disorders and researchers continue to search for new therapies,” Steen said.




Advertise in this space for $10 per month. Contact us today.


Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)